BioRestorative Therapies, Inc. (BRTX) intrinsic value & 10-year financials
BioRestorative Therapies, Inc. (BRTX) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 29.0% a year to $359.7K, with an average return on invested capital of 304.6%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.54
- Market cap
- $13.8M
- Revenue (FY2025)
- $359.7K
- Revenue growth (10-yr CAGR)
- 29.0%
- ROIC (10-yr avg)
- 304.6%
- Free cash flow (FY2025)
- -$10.9M
BRTX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $359.7K | -$14.2M | -$1.58 | -$10.9M | -4350.1% | -320.5% |
| FY2024 | $401.0K | -$9.0M | -$1.16 | -$8.3M | -2881.6% | -89.4% |
| FY2023 | $145.8K | -$14.4M | -$3.42 | -$6.6M | -10439.5% | -100.7% |
| FY2022 | $119.8K | -$18.5M | -$5.11 | -$6.1M | -15838.1% | -239.6% |
| FY2021 | $46.0K | -$44.3M | — | -$3.4M | -57191.0% | 3044.2% |
| FY2020 | $77.0K | -$11.3M | — | — | -3574.1% | 138.4% |
| FY2019 | $130.0K | -$14.6M | — | -$7.0M | -6486.2% | 119.5% |
| FY2018 | $111.0K | -$12.5M | — | -$5.1M | -6889.8% | 161.8% |
| FY2017 | $81.0K | -$9.4M | — | -$3.9M | -10338.6% | 159.6% |
| FY2016 | $36.4K | -$8.6M | — | -$5.2M | -21447.6% | 172.7% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
BioRestorative Therapies, Inc. is a consistent compounder, expanding top-line revenue at 29.0% annually over the past decade.
BioRestorative Therapies, Inc. returns on capital have been average, hovering around 9.8% ROIC over the decade.
BioRestorative Therapies, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, BioRestorative Therapies, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-52.48 per share.